<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080596</url>
  </required_header>
  <id_info>
    <org_study_id>HMM0107</org_study_id>
    <nct_id>NCT04080596</nct_id>
  </id_info>
  <brief_title>DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin</brief_title>
  <official_title>A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics, Pharmadynamics and Safety of HMS5552 Administered Alone or in Combination With Itraconazole in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Medicine Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hua Medicine Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the impact of itraconzaole on the
      pharmacokinetics of Dorzagliatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Actual">December 5, 2017</completion_date>
  <primary_completion_date type="Actual">December 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Peak concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>up to 96 hours</time_frame>
    <description>Area under the curve</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Drug Interaction</condition>
  <arm_group>
    <arm_group_label>Sequential arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dorzagliatin administered alone on Day 1; after wash-out, intraconazole was administered from Day 8 to Day 15, with Dorzagliatin administered together on Day 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dorzagliatin</intervention_name>
    <description>GKA for T2DM currently under clinical development</description>
    <arm_group_label>Sequential arm</arm_group_label>
    <other_name>HMS5552</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-65

          -  Body weight ≥ 50 kg

          -  BMI ≥ 19.0 kg/m2 and ≤ 30.0 kg/m2

          -  HbA1c ≥ 7% and ≤ 10.5%

          -  FPG ≥ 7.5 mmol/L and ≤ 13.3 mmol/L

        Exclusion Criteria:

          -  T1DM

          -  Use of prescription or OTC medications, and herbal within 14 days prior to dosing

          -  Blood donation

          -  Any surgery or treatment that may impact the ADME of the drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The 2nd Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

